Insider Selling: Arvinas, Inc. (NASDAQ:ARVN) Insider Sells 8,658 Shares of Stock

Arvinas, Inc. (NASDAQ:ARVN) insider Noah Berkowitz sold 8,658 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total transaction of $74,372.22. Following the completion of the transaction, the insider now directly owns 110,023 shares in the company, valued at $945,097.57. This trade represents a 7.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Arvinas Trading Up 2.3 %

Arvinas stock traded up $0.19 during midday trading on Wednesday, reaching $8.61. 95,515 shares of the stock traded hands, compared to its average volume of 921,115. The firm has a market cap of $592.20 million, a PE ratio of -3.09 and a beta of 1.95. The company has a 50-day simple moving average of $16.87 and a two-hundred day simple moving average of $21.59. Arvinas, Inc. has a 12-month low of $7.91 and a 12-month high of $44.85.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter last year, the company earned ($2.53) EPS. Equities research analysts anticipate that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Analyst Ratings Changes

ARVN has been the subject of several analyst reports. BMO Capital Markets set a $20.00 target price on Arvinas and gave the company an “outperform” rating in a report on Wednesday, March 12th. Wedbush lowered shares of Arvinas from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $57.00 to $12.00 in a report on Wednesday, March 12th. The Goldman Sachs Group downgraded shares of Arvinas from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $70.00 to $15.00 in a research note on Thursday, March 13th. Stifel Nicolaus dropped their price target on shares of Arvinas from $63.00 to $51.00 and set a “buy” rating for the company in a research note on Wednesday, February 12th. Finally, Wells Fargo & Company set a $26.00 price target on shares of Arvinas and gave the stock an “overweight” rating in a report on Wednesday, March 12th. Five equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, Arvinas currently has an average rating of “Moderate Buy” and a consensus target price of $37.47.

Institutional Trading of Arvinas

Large investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new stake in shares of Arvinas during the 4th quarter worth $28,000. KBC Group NV boosted its position in shares of Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after acquiring an additional 1,255 shares in the last quarter. Quantbot Technologies LP increased its holdings in shares of Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after acquiring an additional 2,601 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Arvinas in the 4th quarter valued at about $171,000. Finally, Tema Etfs LLC acquired a new stake in shares of Arvinas during the 4th quarter worth about $227,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.